307 related articles for article (PubMed ID: 29087320)
1. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
Basudhar D; Glynn SA; Greer M; Somasundaram V; No JH; Scheiblin DA; Garrido P; Heinz WF; Ryan AE; Weiss JM; Cheng RYS; Ridnour LA; Lockett SJ; McVicar DW; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13030-13035. PubMed ID: 29087320
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma is quintessential for NOS2 and COX2 expression in ER
Cheng RYS; Ridnour LA; Wink AL; Gonzalez AL; Femino EL; Rittscher H; Somasundaram V; Heinz WF; Coutinho L; Rangel MC; Edmondson EF; Butcher D; Kinders RJ; Li X; Wong STC; McVicar DW; Anderson SK; Pore M; Hewitt SM; Billiar TR; Glynn SA; Chang JC; Lockett SJ; Ambs S; Wink DA
Cell Death Dis; 2023 May; 14(5):319. PubMed ID: 37169743
[TBL] [Abstract][Full Text] [Related]
3. Inducible nitric oxide synthase-derived extracellular nitric oxide flux regulates proinflammatory responses at the single cell level.
Somasundaram V; Gilmore AC; Basudhar D; Palmieri EM; Scheiblin DA; Heinz WF; Cheng RYS; Ridnour LA; Altan-Bonnet G; Lockett SJ; McVicar DW; Wink DA
Redox Biol; 2020 Jan; 28():101354. PubMed ID: 31683257
[TBL] [Abstract][Full Text] [Related]
4. Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density.
Somasundaram V; Ridnour LA; Cheng RY; Walke AJ; Kedei N; Bhattacharyya DD; Wink AL; Edmondson EF; Butcher D; Warner AC; Dorsey TH; Scheiblin DA; Heinz W; Bryant RJ; Kinders RJ; Lipkowitz S; Wong ST; Pore M; Hewitt SM; McVicar DW; Anderson SK; Chang J; Glynn SA; Ambs S; Lockett SJ; Wink DA
Redox Biol; 2022 Dec; 58():102529. PubMed ID: 36375380
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
6. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.
Switzer CH; Cheng RY; Ridnour LA; Glynn SA; Ambs S; Wink DA
Breast Cancer Res; 2012 Sep; 14(5):R125. PubMed ID: 22971289
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.
Heinecke JL; Ridnour LA; Cheng RY; Switzer CH; Lizardo MM; Khanna C; Glynn SA; Hussain SP; Young HA; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6323-8. PubMed ID: 24733928
[TBL] [Abstract][Full Text] [Related]
8. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
9. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.
Glynn SA; Boersma BJ; Dorsey TH; Yi M; Yfantis HG; Ridnour LA; Martin DN; Switzer CH; Hudson RS; Wink DA; Lee DH; Stephens RM; Ambs S
J Clin Invest; 2010 Nov; 120(11):3843-54. PubMed ID: 20978357
[TBL] [Abstract][Full Text] [Related]
10. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
11. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
12. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Kochel TJ; Reader JC; Ma X; Kundu N; Fulton AM
Oncotarget; 2017 Jan; 8(4):6540-6554. PubMed ID: 28029661
[TBL] [Abstract][Full Text] [Related]
13. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and IGF-I activate the Akt pathway in breast cancer.
Prueitt RL; Boersma BJ; Howe TM; Goodman JE; Thomas DD; Ying L; Pfiester CM; Yfantis HG; Cottrell JR; Lee DH; Remaley AT; Hofseth LJ; Wink DA; Ambs S
Int J Cancer; 2007 Feb; 120(4):796-805. PubMed ID: 17096325
[TBL] [Abstract][Full Text] [Related]
16. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
19. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.
Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J
Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352
[TBL] [Abstract][Full Text] [Related]
20. LncRNA HEIH/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2-induced nitric oxide production.
Nafea H; Youness RA; Abou-Aisha K; Gad MZ
J Cell Physiol; 2021 Jul; 236(7):5362-5372. PubMed ID: 33368266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
